Aerie Pharmaceuticals (AERI) Getting Somewhat Favorable News Coverage, Report Shows
News headlines about Aerie Pharmaceuticals (NASDAQ:AERI) have been trending somewhat positive on Monday, Accern Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aerie Pharmaceuticals earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.1731786055257 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news articles that may have effected Accern’s analysis:
- Aerie Initiates Phase III Study for Ophthalmic Drug Roclatan – Nasdaq (nasdaq.com)
- BRIEF-Aerie Pharmaceuticals initiates Mercury 3 clinical trial of Roclatantm 0.02 pct/0.005 pct (reuters.com)
- Aerie Pharmaceuticals, Inc. (AERI) Earns Buy Rating from Analysts at Mizuho (americanbankingnews.com)
- Dermira, Inc. (DERM) is at $23.43 per share and Aerie Pharmaceuticals, Inc. (AERI) is listed at $57.50 – Stocks Gallery (stocksgallery.com)
- Aerie Pharmaceuticals Initiates Mercury 3 Clinical Trial of … – Business Wire (press release) (businesswire.com)
Aerie Pharmaceuticals (AERI) opened at 58.25 on Monday. Aerie Pharmaceuticals has a 1-year low of $19.09 and a 1-year high of $59.80. The company’s market cap is $2.12 billion. The stock has a 50 day moving average of $54.43 and a 200-day moving average of $49.41.
Aerie Pharmaceuticals (NASDAQ:AERI) last announced its earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.84) by $0.02. On average, equities research analysts predict that Aerie Pharmaceuticals will post ($2.59) earnings per share for the current year.
AERI has been the subject of a number of analyst reports. Zacks Investment Research cut shares of Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. HC Wainwright restated a “buy” rating and set a $69.00 price target on shares of Aerie Pharmaceuticals in a research note on Thursday, May 25th. BidaskClub cut shares of Aerie Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 17th. Stifel Nicolaus restated a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Friday, May 26th. Finally, Aegis raised their price target on shares of Aerie Pharmaceuticals from $63.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, May 25th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have assigned a buy rating to the company. Aerie Pharmaceuticals has an average rating of “Buy” and a consensus price target of $66.36.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Stock Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.